New hope for kids with rare kidney disease: drug trial targets protein leak
NCT ID NCT07498335
First seen Apr 03, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This study tests a drug called atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage, over 36 weeks. Participants will take the drug and be monitored for safety and side effects. This is a phase 3 trial, meaning it's in the final testing stage before possible approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.